“We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals,” said Kevin Hykes, President and Chief Executive ...
Building on long-term data announced earlier this year, CVRx has reported durable improvements in heart failure patients with its Barostim device over 24 months. The results, published in the Journal ...
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...
CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...
Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...
The number of Americans living with congestive heart failure is on the rise; it’expected to affect more than eight million people by 2030. For many of those patients, medications stop working. Now a ...
CVRx Inc., the Brooklyn Park-based medical device maker, went public on Wednesday, raising $126 million. The shares were priced at $18 for the initial public offering. When they started trading late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback